A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects

Wu Min; Sun Jixuan; Wu DandanXu JiaWei JinWang ZhaoheYu JinchenLi ShengfengZhang HongDing Yanhua

首页> 外文期刊>Expert opinion on investigational drugs >A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects

【24h】

A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects

机译：A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Background: To compare the pharmacokinetic (PK) profile, safety, and immunogenicity between golimumab and the biosimilar BAT2506 in healthy Chinese male subjects.

著录项

来源
《Expert opinion on investigational drugs》 |2021年第6期|77-83|共7页
作者
Wu Min; Sun Jixuan; Wu DandanXu JiaWei JinWang ZhaoheYu JinchenLi ShengfengZhang HongDing Yanhua;
展开▼
作者单位

First Hosp Jilin Univ, Dept Phase Clin Trial Unit 1, Changchun 130021, Jilin, Peoples R China;

Biothera Solut Ltd, Guangzhou, Guangdong, Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
BAT2506; biosimilar; safety; pharmacokinetics; immunogenicity;

A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects

摘要

著录项

相关主题

期刊订阅